Pay in 4 interest-free payments of $5.17 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Phase 1a: First-in-Human Single Ascending Dose Study (NCT02951806) Study Title: "Safety, Tolerability, and Pharmacokinetics of Single Doses of Cagrilintide in Healthy Subjects" Status: Completed Phase: Phase 1a Enrollment: 48 healthy volunteers Study Period: 2016-2017 Location: Single center (Denmark) Design: Randomized, double-blind, placebo-controlled, single ascending dose Dose Range: 0.03-10 mg SC Primary Endpoints: Safety, tolerability, PK parameters Population: Healthy male subjects, BMI 20-28 Key Results: Pharmacokinetics: Terminal half-life 5-7 days across dose range
Other times, weight loss is not long-term, as weight gain quickly resumes after people stop taking the medication
Net Weight: 135 g
Select optionsPeptides Klotho (alphaKlothoLR) (20mcg) $499.00 $10,179.60Price range: $499.00 through $10,179.60 $249.50 $5,089.80Price range: $249.50 through $5,089.80 This product has multiple variants
US$ 27.72
US$ 29.84
US$ 23.30
US$ 26.76
US$ 20.92
US$ 28.86
US$ 28.64
